VBI Vaccines Current Ratio 2016-2021 | VBIV

VBI Vaccines current ratio from 2016 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
VBI Vaccines Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.15B $0.03B 5.60
2021-03-31 $0.15B $0.02B 6.11
2020-12-31 $0.13B $0.02B 7.61
2020-09-30 $0.13B $0.01B 9.06
2020-06-30 $0.09B $0.02B 5.86
2020-03-31 $0.04B $0.03B 1.30
2019-12-31 $0.05B $0.03B 1.58
2019-09-30 $0.06B $0.03B 1.88
2019-06-30 $0.03B $0.04B 0.95
2019-03-31 $0.05B $0.02B 1.99
2018-12-31 $0.06B $0.02B 2.64
2018-09-30 $0.03B $0.02B 1.61
2018-06-30 $0.05B $0.02B 2.75
2018-03-31 $0.06B $0.02B 3.77
2017-12-31 $0.07B $0.01B 5.32
2017-09-30 $0.01B $0.01B 1.03
2017-06-30 $0.02B $0.01B 2.00
2017-03-31 $0.03B $0.01B 3.31
2016-12-31 $0.03B $0.01B 4.51
2016-09-30 $0.00B 0.00
2016-06-30 $0.00B 0.00
2016-03-31 $0.00B 0.00
2015-12-31 $0.02B $0.00B 4.97
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.853B $0.001B
VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company's eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus vaccine. Its second platform is a thermostable technology that enables the development of vaccines and biologics. VBI Vaccines Inc., formerly known as SciVac Therapeutics, Inc., is headquartered in Cambridge, MA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71